Navigation Links
A&G Pharmaceutical Receives $870,000 Grant from Avon Foundation to Advance Innovative Blood Diagnostic Test for Early Detection of Breast Cancer
Date:12/14/2007

COLUMBIA, Md., Dec. 14 /PRNewswire/ -- A&G Pharmaceutical announced today that the Avon Foundation Breast Cancer Prevention Research Initiative has awarded A&G an $870,000 grant to conduct multicenter clinical studies focused on measuring levels of A&G's proprietary breast cancer biomarker, GP88, in blood and tissue samples from breast cancer patients. Results of the studies could provide the basis for developing a blood test that would enable early detection of breast cancer.

The award was one of 12 grants totaling more than $7 million awarded this year by the Avon Foundation as part of its Breast Cancer Prevention Research Initiative, and it is the first ever awarded by the foundation to a private company.

The GP88 blood diagnostic test is one of two breast cancer test kits in late-stage development by A&G. In addition to the blood test, A&G is developing a tissue biopsy test that would help pathologists and oncologists predict risk of recurrence in breast cancer patients. Both diagnostic tests are based on A&G's patented, proprietary GP88 growth factor, a protein found in circulating blood and tissue of breast cancer patients. Concurrently, A&G is developing a monoclonal antibody therapeutic that neutralizes the function of GP88 in breast cancer. The National Cancer Institute recently awarded A&G a $120,000 Phase I Small Business Innovation Research (SBIR) grant to support development of this new anti-GP88 therapeutic.

"Breast cancer is the most commonly diagnosed cancer in women-a projected 1.2 million new cases of breast cancer will be diagnosed this year-and early detection, when the disease is most treatable, continues to be a major worldwide challenge," said Carol Kurzig, Executive Director of the Avon Foundation. "We are very pleased to make this award to A&G Pharmaceutical, whose highly sensitive GP88 test has the potential to detect breast cancer cells at the earliest stage of the disease."

"We greatly appreciate Avon's
'/>"/>

SOURCE A&G Pharmaceutical
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... 2015 According to a new market ... For Transgenic Crops (Corn, Soybean, Cotton and Others), Synthetic ... Share, Growth, Trends and Forecast, 2013 – 2019,”the global ... in 2012 and is expected to reach USD 28,694.1 ... from 2013 to 2019. , Demand for food ...
(Date:2/26/2015)... 26, 2015 Regis Technologies announced ... of oncology drug substances. , Regis Technologies is proud ... new Potent Compound Suite (PCS) for 2015. , Regis ... foot, cGMP facility in Morton Grove, Illinois. The PCS ... potent compounds up to about one kilogram per batch. ...
(Date:2/26/2015)... , Feb. 26, 2015 Tauriga Sciences, Inc. ... company with interests in the natural wellness sector and ... today that its products will be featured at the ... Partners, 27 th Annual Growth Stock Conference on ... at 1 Ritz Carlton Drive, Dana Point ...
(Date:2/26/2015)... Texas , Feb. 26, 2015   Lexicon Pharmaceuticals, ... Lexicon management will present at the Cowen 35 th ... 8:40 a.m. EST in Boston .  Lexicon ... and milestones. A webcast of the presentation will ... archived version of the presentation will be available at ...
Breaking Biology Technology:Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 3Regis Extends cGMP Services to Oncology Market 2SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 2SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 3SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 4Lexicon To Present At The Cowen 35th Annual Health Care Conference 2
... Rhythm announced today the results of a Phase 1b ... for the treatment of diabetic gastroparesis. The trial demonstrated ... diabetic gastroparesis. The findings were presented at the Digestive ... The Phase 1b clinical trial was a randomized, double-blind, ...
... To become better healers, tissue engineering need a timely and ... already are or can become the tissue they need to ... that the stiffness, viscosity, and other mechanical properties of adult ... predict whether they will turn into bone, cartilage, or fat. ...
... New York, May 21, 2012 Elsevier,s Computers & ... on 3D Object Retrieval which will incorporate the Collage Authoring ... place winner of the 2011 Executable Paper Grand Challenge. The ... Eurographics 2012 on May 13, during the 3DOR Workshop. ...
Cached Biology Technology:Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Diabetic Gastroparesis 2Physical properties predict stem cell outcome 2Physical properties predict stem cell outcome 3
(Date:2/5/2015)...   Epic Sciences , a precision diagnostics company dedicated ... Murali Prahalad , Ph.D., president and CEO, is scheduled to ... 2015: Silicon Valley, which is taking place at the Computer ... on January 26-28, 2015. Dr. Prahalad will ... Last year, Epic Sciences was a finalist in the PMWC,s ...
(Date:2/5/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announces it ... Conference on January 29 th at 10:30 a.m. ... of NXT-ID will present and host a live Q&A ... and its full suite of biometric technologies. Investors can ...
(Date:1/22/2015)... DUBLIN , Jan. 22, 2015 Research and Markets ... "Biometrics - A Global Market Overview" report to ... biometrics technology is to ensure that an individual is who ... technology may make use of a person,s unique physical characteristics, ...
Breaking Biology News(10 mins):Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
... to botulinum neurotoxins, which are among the most potent ... a bacterium found in soil and food. In the ... with nerve transmission and disrupting the communication between the ... botulinum toxins leads to an often-fatal paralysis, which is ...
... that transplanting human stem cells into spinal cords of ... start of nerve cell damage typical of the disease ... into nerve cells that make substantial connections with existing ... also known as amyotrophic lateral sclerosis (ALS). The study ...
... Researchers at the University of Pennsylvania School of Medicine ... leukemia (AML). Several lines of evidence point to a ... took over the starship Enterprise in the original Star ... , "Tribbles had never been directly linked ...
Cached Biology News:Human stem cells delay start of Lou Gehrig's disease in rats 2Human stem cells delay start of Lou Gehrig's disease in rats 3'Tribbles' protein implicated in common and aggressive form of leukemia 2
... from E. coli is a ... also contains both 5'--3'and 3'--5' ... activity enables the enzyme to ... the DNA as starting points ...
DNase I (Deoxyribonuclease I) digests single- and double-stranded DNA to oligodeoxyribonucleotides. Ribonuclease activity has been reduced to non-detectable levels....
... thymus Description: Topoisomerase I relaxes both ... breakage and rejoining of phosphodiester bonds (1,2) . ... to be differentiated by a single nucleotide pair ... active in the absence of Mn 2+ ...
...
Biology Products: